Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 7/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | OXTR | P30559 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20176885 | 0.88 | SLC6A2 (0.53) | SLC6A2SLC6A3SLC6A4GRIN1GRIN2B | |
| SCHEMBL20165881 | 0.79 | SLC6A4 (0.60) | SLC6A2SLC6A3SLC6A4GRIN1GRIN2B | |
| SCHEMBL20176372 | 0.78 | SLC6A4 (0.36) | SLC6A2SLC6A3SLC6A4OXTR | |
| SCHEMBL24180233 | 0.76 | SLC6A2 (0.70) | SLC6A2SLC6A3SLC6A4GRIN1GRIN2B | |
| SCHEMBL20176375 | 0.75 | SLC6A4 (0.55) | SLC6A2SLC6A3SLC6A4GRIN1GRIN2B | |
| SCHEMBL22817806 | 0.75 | SLC6A2 (0.55) | SLC6A2SLC6A3SLC6A4GRIN1GRIN2B | |
| SCHEMBL3117365 | 0.71 | SLC6A2 (0.64) | SLC6A2SLC6A3SLC6A4GRIN1GRIN2B | |
| SCHEMBL20176345 | 0.71 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4HTR1A | |
| SCHEMBL28422963 | 0.71 | SLC6A2 (0.64) | SLC6A2SLC6A3SLC6A4GRIN1GRIN2B | |
| SCHEMBL20165809 | 0.71 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541784-B1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2023-09-13 | — | — | EP | disclosed |
| US-10875829-B1 | Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2020-12-29 | — | — | US | disclosed |
| WO-2018091687-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875829-B1 | Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | SLC18A1, CHRM1, CHRM2 | SLC6A2 21/4885SLC6A3 15/4885SLC6A4 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.